[1]陈 斐.卵巢癌患者血液NLR、MLR、PLR的变化及其临床意义[J].医学信息,2021,34(17):79-82.[doi:10.3969/j.issn.1006-1959.2021.17.020]
　CHEN Fei.Changes of Blood NLR, MLR and PLR in Patients with Ovarian Cancer and Their Clinical Significance[J].Medical Information,2021,34(17):79-82.[doi:10.3969/j.issn.1006-1959.2021.17.020]
点击复制

卵巢癌患者血液NLR、MLR、PLR的变化及其临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年17期
页码:
79-82
栏目:
论著
出版日期:
2021-09-01

文章信息/Info

Title:
Changes of Blood NLR, MLR and PLR in Patients with Ovarian Cancer and Their Clinical Significance
文章编号:
1006-1959（2021）17-0079-04
作者:
陈 斐
（浙江大学医学院附属妇产科医院检验科，浙江 杭州 310006）
Author(s):
CHEN Fei
(Department of Laboratory Medicine,Obstetrics and Gynecology Hospital,Zhejiang University School of Medicine, Hangzhou 310006,Zhejiang,China)
关键词:
卵巢癌; 中性粒细胞淋巴细胞比率; 单核细胞淋巴细胞比率; 血小板淋巴细胞比率; 糖类抗原125; 淋巴结转移
Keywords:
Ovarian cancer; Neutrophil-lymphocyte ratio; Monocyte-lymphocyte ratio; Platelet-lymphocyte ratio; Carbohydrate antigen 125; Lymph node metastasis
分类号:
R737.31；R730.43
DOI:
10.3969/j.issn.1006-1959.2021.17.020
文献标志码:
A
摘要:
目的 探讨卵巢癌患者术前中性粒细胞淋巴细胞比率（NLR）、单核细胞淋巴细胞比率（MLR）和血小板淋巴细胞比率（PLR）的变化及临床意义。方法 选取2014年1月-2018年8月在浙江大学医学院附属妇产科医院收治的卵巢癌患者324例为卵巢癌组，另选取同期健康体检者821例为正常组，检测外周血常规中NLR、MLR、PLR及糖类抗原125（CA125）水平，分析NLR、MLR、PLR与卵巢癌临床病理特征（临床分期、淋巴结转移、腹水）的关系及其在卵巢癌的诊断效能。结果 与正常组相比，卵巢癌组NLR、MLR和PLR显著升高（P＜0.05）；NLR、MLR、PLR水平与卵巢癌患者临床分期、有无淋巴结转移、有无腹水相关（P＜0.05）。ROC曲线分析表明，NLR、MLR、PLR和CA125对卵巢癌的诊断效能分别为（AUC=0.791、0.736、0.728、0.894），四项指标联合诊断较单个指标具有更高的诊断效率（AUC=0.929，Se=82.10%，Sp=92.45%）。结论 NLR、MLR、PLR在卵巢癌患者中升高，且与临床分期、是否淋巴结转移、有无腹水相关，联合诊断相比于单个指标具有更高的诊断效能，有助于卵巢癌的诊断。
Abstract:
Objective To investigate the changes and clinical significance of neutrophil lymphocyte ratio (NLR), monocyte lymphocyte ratio (MLR) and platelet lymphocyte ratio (PLR) in patients with ovarian cancer before operation.Methods A total of 324 ovarian cancer patients who were admitted to the Obstetrics and Gynecology Hospital of Zhejiang University School of Medicine from January 2014 to August 2018 were selected as the ovarian cancer group.In addition, 821 healthy patients during the same period were selected as the normal group, and the levels of NLR, MLR, PLR and carbohydrate antigen 125 (CA125) in the routine peripheral blood were tested.Analyze the relationship between NLR, MLR, PLR and clinicopathological characteristics of ovarian cancer (clinical stage, lymph node metastasis, ascites) and its diagnostic efficacy in ovarian cancer. Results Compared with the normal group, NLR, MLR and PLR in the ovarian cancer group were significantly higher (P＜0.05);The levels of NLR, MLR, and PLR were related to the clinical stage of patients with ovarian cancer, the presence or absence of lymph node metastasis, and the presence or absence of ascites (P＜0.05).ROC curve analysis showed that the diagnostic efficacy of NLR, MLR, PLR and CA125 for ovarian cancer were (AUC=0.791, 0.736, 0.728, 0.894), respectively.The combined diagnosis of four indicators had a higher diagnostic efficiency than a single indicator (AUC=0.929, Se=82.10%, Sp=92.45%).Conclusion NLR, MLR, and PLR are elevated in patients with ovarian cancer and are related to clinical stage, lymph node metastasis, and ascites.Compared with a single index, the combined diagnosis has higher diagnostic efficiency, which is helpful for the diagnosis of ovarian cancer patients.

参考文献/References:

[1]Siegel RL,Miller KD,Jemal A.Cancer Statistics,2017[J].Ca Cancer J Clin,2017,67(1):7-30. [2]李宏岩,胡玉红,于晓迪.错配修复基因在Lynch综合征及相关卵巢癌的研究[J].医学信息,2020,33(18):36-38. [3]孙培松,白雪,库亚西克孜·努尔买买提,等.血清HE4、B7H4水平变化与卵巢癌分期、淋巴结转移的关系及其诊断价值[J].医学信息,2020,33(16):88-90. [4]王学芹,满霞霞,刘东珍,等.晚期上皮性卵巢癌患者5年生存率的影响因素[J].中国妇幼保健,2020,35(24):4837-4839. [5]Morgan RJ,Armstrong DK,Alvarez RD,et al.Ovarian Cancer,Version 1.2016[J].J Natl Compr Canc Ne,2016,14(9):1134-1163. [6]Dochez V,Caillon H,Vaucel E,et al.Biomarkers and algorithms for diagnosis of ovarian cancer:CA125,HE4,RMI and ROMA,a review[J].J Ovarian Res,2019,12(1):28. [7]Todoric J,Antonucci L,Karin M.Targeting Inflammation in Cancer Prevention and Therapy[J].Cancer Prev Res,2016,9(12):895-905. [8]Balkwill F,Mantovani A.Inflammation and cancer:back to Virchow[J].Lancet,2001,357(9255):539-545. [9]李飞霞,田刚,余婷,等.血清CA125、HE4联合PLR、NLR、MLR诊断上皮性卵巢癌的临床价值[J].山东医药,2020,60(10):70-72. [10]Shoji F,Kozuma Y,Toyokawa G,et al.Complete Blood Cell Count-Derived Inflammatory Biomarkers in Early-Stage Non-Small-Cell Lung Cancer[J].Ann Thorac Cardiovas,2020,26(5):248-455. [11]Abu-Shawer O,Abu-Shawe RM,Haimour A,et al.Hematologic markers of distant metastases in gastric cancer[J].J Gastrointest Oncol,2019,10(3):529-536. [12]Chao B,Ju XL,Zhang LR,et al.A Novel Prognostic Marker Systemic Inflammation Response Index(SIRI)for Operable Cervical Cancer Patients[J].Front Oncol,2020(10):766. [13]Huang HP,Liu Q,Zhu LX,et al.Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer[J].Sci Rep,2019,9(1):3284. [14]Li Z,Hong N,Robertson M,et al.Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer[J].Sci Rep,2017(7):43001. [15]Abu-Shawer O,Abu-Shawer M,Hirmas N,et al.Hematologic markers of distant metastases and poor prognosis in gynecological cancers[J].BMC Cancer,2019,19(1):141. [16]Xiang JD,Zhou LN,Li X,et al.Preoperative Monocyte-to-Lymphocyte Ratio in Peripheral Blood Predicts Stages,Metastasis,and Histological Grades in Patients with Ovarian Cancer[J].Transl Oncol,2017,10(1):33-39. [17]李飞霞.血清CA125、HE4联合PLR、NLR、MLR在上皮性卵巢癌诊断中的应用研究[D].兰州:兰州大学,2020.

相似文献/References:

[1]杨廷双.卵巢癌患者经CT检查和MRI检查的临床效果对比[J].医学信息,2018,31(07):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
　YANG Ting-shuang.Comparison of Clinical Effects between CT and MRI in Patients with Ovarian Cancer[J].Medical Information,2018,31(17):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
[2]揭嘉慧,张 颖.卵巢癌与非编码RNA研究进展[J].医学信息,2019,32(05):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
　JIE Jia-hui,ZHANG Ying.Progress in Research on Ovarian Cancer and Non-coding RNA[J].Medical Information,2019,32(17):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
[3]林斯婕,吴 璇,覃 桓,等.卵巢癌合并2型糖尿病发生的危险因素分析[J].医学信息,2019,32(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
　LIN Si-jie,WU Xuan,QIN Huan,et al.Analysis of Risk Factors for Ovarian Cancer Complicated with Type 2 Diabetes[J].Medical Information,2019,32(17):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
　LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,32(17):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]许书凡,庞 华.18F-FDGPET/CT在卵巢癌中的应用研究[J].医学信息,2019,32(08):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
　XU Shu-fan,PANG Hua.Research on the Application of 18F-FDGPET/CT in Ovarian Cancer[J].Medical Information,2019,32(17):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
[6]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
　ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(17):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[7]黄馨禾,董丹丹,刘 倩.PARP抑制剂在卵巢癌治疗中的研究现状[J].医学信息,2019,32(21):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
　HUANG Xin-he,DONG Dan-dan,LIU Qian.Research Status of PARP Inhibitors in the Treatment of Ovarian Cancer[J].Medical Information,2019,32(17):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
[8]王 秦,张家佳,刘成桂,等.高表达IL-12卵巢癌细胞的建立[J].医学信息,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
　WANG Qin,ZHANG Jia-jia,LIU Cheng-gui,et al.Establishment of High Expression of IL-12 Ovarian Cancer Cells[J].Medical Information,2019,32(17):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
[9]钟达媚,张 颖.PCG与卵巢癌关系的研究[J].医学信息,2020,33(01):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
　ZHONG Da-mei,ZHANG Ying.Study on the Relationship Between PCG and Ovarian Cancer[J].Medical Information,2020,33(17):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
[10]魏绮琪,张 颖.miR-200c与卵巢癌关系的研究[J].医学信息,2020,33(03):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]
　WEI Qi-qi,ZHANG Ying.Study on the Relationship Between miR-200c and Ovarian Cancer[J].Medical Information,2020,33(17):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]

更新日期/Last Update: 1900-01-01